NCT04834544View on ClinicalTrials.gov

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

October 20, 2024

Study Completion Date

April 20, 2027

Conditions
Epithelial Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
Interventions
COMBINATION_PRODUCT

DCVAC/OvCa

An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines

COMBINATION_PRODUCT

Placebo

Placebo

Trial Locations (1)

100191

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
collaborator

SOTIO a.s.

INDUSTRY

lead

Peking University Third Hospital

OTHER